



ACTIVITY OF NEW ANTIBACTERIAL PRODUCTS ON PRIORITY PATHOGENS

Authors: Claudia Agyeere (@Agyeere9), Gideon Danso (@Gideon_0703), Akeemat Ayinla (@That_Hakeemah), Frederick Allou (@Freddie), Duong Gia Khanh(@Khanh)

This infographic presents a summary of the results of testing new antibacterial products on WHO-classified priority pathogens.


- ✓

The AMR products tested were of two types: the traditionally used antibiotics and non-traditional products.
- ✓


Antibiotics made up the majority (57.2%) of the product type.
- ✓

Out of the 669 antibacterial entries tested, 146 (21.8%) showed activity against priority pathogens.
- ✓

The antibacterials tested were most active against Critical Priority Pathogens.



An overview of Active against priority pathogens




- ✓

Majority of the products tested were in development phase I.
- ✓

Activity against priority pathogens is highest when drugs are administered via the intravenous route (IV).

Distribution of R & D Phase



Number of 'Yes' for Active Pathogens by Pathogen Name

